← Back to all trials
Recruiting
NCT05673031
68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors
Conditions: Neuroendocrine Tumors (NET)
Sex: All
Ages: 18 Years – 100 Years
Enrollment: 500
Sponsor: Alberta Health services
Location: Canada
Summary
To determine if 68Ga-HA-DOTATATE PET/CT imaging is effective at diagnosing somatostatin positive tumors compared to conventional imaging [including CT, MRI, 111 In-pentetreotide Scans, 18F-FDG PET/CT, as available]
Eligibility Criteria
Inclusion Criteria:Male or female.
If female of child-bearing potential and outside of the window of 10 days since the last menstrual period, a negative pregnancy test will be required.Age greater than or equal to 18 years.Able and willing to follow instructions and comply with the protocol.Provide written informed consent prior to participation in the study.Clinically suspected (patients presenting with symptom(s) suggestive of carcinoid syndrome or biochemically suggestive of Neuroendocrine Tumor) or Biopsy proven Neuroendocrine TumorExclusion Criteria:Nursing or pregnant females.Age less than 18 years.Surgery in the area of interest within the preceding 2 months.
Source: ClinicalTrials.gov (NCT05673031). StuddyBuddy aggregates publicly available trial information.
